Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
75,000
Stocks News & Analysis
stocks
Are ASX REITs the better way to own property?
Cheap valuations, strong yields and a changing Aussie property landscape.
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,272.00 | 10.00 | -0.11% |
| CAC 40 | 8,636.80 | 13.76 | -0.16% |
| DAX 40 | 26,440.31 | 140.57 | 0.53% |
| Dow JONES (US) | 53,732.41 | 107.58 | -0.20% |
| FTSE 100 | 10,750.11 | 22.56 | -0.21% |
| HKSE | 25,521.99 | 405.14 | 1.61% |
| NASDAQ | 26,729.16 | 73.86 | -0.28% |
| Nikkei 225 | 68,895.98 | 182.18 | 0.27% |
| NZX 50 Index | 13,782.81 | 71.57 | -0.52% |
| S&P 500 | 7,785.76 | 13.23 | -0.17% |
| S&P/ASX 200 | 9,068.30 | 11.00 | -0.12% |
| SSE Composite Index | 3,960.19 | 33.01 | 0.84% |